H.C. Wainwright analyst Robert Burns raised the firm’s price target on SpringsWorks Therapeutics to $105 from $99 and keeps a Buy rating on the shares following the 2022 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- SpringsWorks Therapeutics reports Q4 EPS ($1.19), consensus ($1.22)
- SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
- SpringsWorks announces FDA acceptance, priority review of nirogacestat NDA
- SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
- SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference